How CMS independence is at the forefront of its Alzheimer's drug coverage decision

Zachary Brennan

Senior Editor

Depending on who you ask, the Centers for Medicare and Medicaid Services’ (CMS) decision last week to restrict payment for amyloid-targeted Alzheimer’s drugs was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

How CMS independence is at the forefront of its Alzheimer's drug coverage decision

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Nura Bio raises $68M for clinical tests of SARM1 inhibitor to potentially slow or prevent nerve degeneration

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

Breaking down silos with a new quantitative approach to drug development

How CMS in­de­pen­dence is at the fore­front of its Alzheimer's drug cov­er­age de­ci­sion

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

How CMS independence is at the forefront of its Alzheimer's drug coverage decision